AstraZeneca Forks Over $600M For Actavis Respiratory Drugs
British drugmaker AstraZeneca PLC deepened its growth-by-acquisition strategy on Thursday with a $600 million agreement to acquire Actavis PLC's branded respiratory business in the U.S. and Canada....To view the full article, register now.
Already a subscriber? Click here to view full article